30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
KY Biotechnology & Medical Research

Crescent Biopharma Inc (CBIO)

Track

The most recent insider trading activity occurred on December 4, 2025, with a significant buy transaction by Fairmount Funds Management LLC. Prior to this, Invus Public Equities, L.P. engaged in a series of sell transactions throughout August and July 2024. Earlier buys were made by executives Rock Edwin and Hahn Brian M. in June 2024 and September 2023.
Stock chart
Ticker: CBIO Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Fairmount Funds Management LLC
1 purchase — total 18,237,600 USD
Buy 4 Dec 2025
Value US$1,703,165.48 | Price 330.33 | Shares 20,968
Sale 8 Aug 2024
Value US$1,063,940.63 | Price 39.61 | Shares 12,651
Sale 7 Aug 2024
Value US$11,196.96 | Price 0.18 | Shares 61,488
Sale 6 Aug 2024
Value US$10,187.81 | Price 0.18 | Shares 55,732
Sale 5 Aug 2024
Value US$30,996.13 | Price 0.19 | Shares 164,523
Sale 2 Aug 2024
Value US$57,354.48 | Price 0.20 | Shares 286,200
Sale 1 Aug 2024
Value US$13,742.54 | Price 0.22 | Shares 63,564
Sale 30 Jul 2024
Value US$167,184.85 | Price 0.22 | Shares 756,835
Sale 29 Jul 2024
Value US$85,637.20 | Price 0.24 | Shares 363,949
Sale 26 Jul 2024
Value US$62,439.57 | Price 0.24 | Shares 258,335
Buy 21 Jun 2024
Value US$30,716.50 | Price 0.27 | Shares 115,000
Buy 20 Jun 2024
Value US$48,108.00 | Price 0.25 | Shares 190,000
Buy 18 Jun 2024
Value US$4,334.75 | Price 0.25 | Shares 17,500
Buy 22 Sep 2023
Value US$41,956.14 | Price 1.38 | Shares 30,403
Buy 21 Sep 2023
Value US$48,300.00 | Price 1.38 | Shares 35,000
Sale 17 May 2023
Value US$7,215.00 | Price 1.95 | Shares 3,700
Proposed sale 17 May 2023
Value US$8,453.48 | Price 1.96 | Shares 4,313
Buy 10 May 2023
Value US$46,800.00 | Price 1.56 | Shares 30,000
Buy 8 May 2023
Value US$21,195.00 | Price 1.57 | Shares 13,500
Buy 24 Feb 2023
Value US$170,000.00 | Price 1.70 | Shares 100,000
Buy 23 Feb 2023
Value US$350,760.00 | Price 1.75 | Shares 200,000
Buy 22 Feb 2023
Value US$268,995.00 | Price 1.79 | Shares 150,000
Buy 21 Feb 2023
Value US$92,500.00 | Price 1.85 | Shares 50,000
Buy 17 Feb 2023
Value US$341,000.00 | Price 1.71 | Shares 200,000
Buy 16 Feb 2023
Value US$531,128.63 | Price 1.68 | Shares 315,266
Buy 15 Feb 2023
Value US$2,155,800.00 | Price 2.16 | Shares 1,000,000
Buy 9 Feb 2023
Value US$37,123.00 | Price 3.24 | Shares 11,451
Sale 26 Jan 2023
Value US$4,213,785.73 | Price 3.12 | Shares 1,351,092
Sale 26 Jan 2023
Value US$5,142,614.27 | Price 3.12 | Shares 1,648,908
Sale 25 Jan 2023
Value US$958,427.92 | Price 3.26 | Shares 293,645
Sale 25 Jan 2023
Value US$1,169,687.11 | Price 3.26 | Shares 358,371
Sale 5 Jan 2023
Value US$88,658.65 | Price 2.76 | Shares 32,139
Sale 5 Jan 2023
Value US$108,200.57 | Price 2.76 | Shares 39,223
Sale 4 Jan 2023
Value US$133,642.52 | Price 2.91 | Shares 45,930
Sale 4 Jan 2023
Value US$163,100.32 | Price 2.91 | Shares 56,054
Sale 3 Jan 2023
Value US$235,410.57 | Price 2.99 | Shares 78,730
Sale 3 Jan 2023
Value US$287,300.77 | Price 2.99 | Shares 96,084
Sale 30 Dec 2022
Value US$165,027.90 | Price 3.02 | Shares 54,645
Sale 30 Dec 2022
Value US$201,403.80 | Price 3.02 | Shares 66,690
Buy 22 Dec 2022
Value US$247,500.00 | Price 2.25 | Shares 110,000
Buy 17 Nov 2022
Value US$37,400.00 | Price 1.87 | Shares 20,000
Buy 15 Nov 2022
Value US$166,000.00 | Price 1.66 | Shares 100,000
Buy 14 Nov 2022
Value US$143,000.00 | Price 1.43 | Shares 100,000
Buy 11 Nov 2022
Value US$25,026.00 | Price 1.29 | Shares 19,400
Buy 11 Nov 2022
Value US$32,250.00 | Price 1.29 | Shares 25,000
Buy 11 Nov 2022
Value US$21,200.00 | Price 1.06 | Shares 20,000
Buy 11 Nov 2022
Value US$6,825.00 | Price 1.05 | Shares 6,500
Buy 11 Nov 2022
Value US$52,702.65 | Price 1.17 | Shares 45,045
Sale 9 Mar 2022
Value US$3,179.53 | Price 1.09 | Shares 2,917
Sale 9 Mar 2022
Value US$3,517.43 | Price 1.09 | Shares 3,227
Sale 9 Mar 2022
Value US$2,549.51 | Price 1.09 | Shares 2,339
Buy 16 Nov 2021
Value US$82,000.00 | Price 2.05 | Shares 40,000
Planned sale 28 Dec 2020
Value US$329,128.16 | Price 3.91 | Shares 84,176
Buy 4 Nov 2020
Value US$223,834.00 | Price 2.60 | Shares 86,090
Buy 4 Nov 2020
Value US$1,316,003.00 | Price 2.60 | Shares 506,155
Buy 4 Nov 2020
Value US$1,753,679.20 | Price 2.60 | Shares 674,492
Buy 30 Oct 2020
Value US$42,548.00 | Price 2.75 | Shares 15,472
Buy 30 Oct 2020
Value US$689,576.25 | Price 2.75 | Shares 250,755
Buy 30 Oct 2020
Value US$1,832,558.75 | Price 2.75 | Shares 666,385
Buy 9 Mar 2020
Value US$68,000.00 | Price 3.40 | Shares 20,000
Buy 5 Sep 2019
Value US$397,609.99 | Price 3.18 | Shares 124,956
Buy 5 Sep 2019
Value US$2,195,051.79 | Price 3.18 | Shares 689,834
Buy 5 Sep 2019
Value US$2,717,287.99 | Price 3.18 | Shares 853,956
Buy 13 Aug 2019
Value US$31,800.00 | Price 3.18 | Shares 10,000
Sale 18 Oct 2018
Value US$49,448.54 | Price 14.02 | Shares 3,527
Sale 17 Oct 2018
Value US$101,822.00 | Price 14.00 | Shares 7,273
Sale 16 Oct 2018
Value US$198,942.00 | Price 14.01 | Shares 14,200
Sale 11 Jun 2018
Value US$348,983.80 | Price 18.04 | Shares 19,345
Sale 10 May 2018
Value US$98,542.73 | Price 17.81 | Shares 5,533
Sale 10 May 2018
Value US$71,346.86 | Price 17.81 | Shares 4,006
Sale 10 May 2018
Value US$98,542.73 | Price 17.81 | Shares 5,533
Sale 10 May 2018
Value US$71,346.86 | Price 17.81 | Shares 4,006
Sale 10 May 2018
Value US$98,542.73 | Price 17.81 | Shares 5,533
Sale 10 May 2018
Value US$71,346.86 | Price 17.81 | Shares 4,006
Sale 10 May 2018
Value US$98,542.73 | Price 17.81 | Shares 5,533
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-08 2025-12-04 B Purchase
3.5
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
20,968 -26.7%
330.33
US$1,703,165 		20,968 -26.7% 330.33 US$1,703,165
2024-08-09 2024-08-08 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
12,651 -12.6%
39.61
US$1,063,941 		12,651 -12.6% 39.61 US$1,063,941
2024-08-09 2024-08-07 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
79,775 +11.6%
189.78
US$402,129 		79,775 +11.6% 189.78 US$402,129
2024-08-07 2024-08-06 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
55,732 -0.8%
0.18
US$10,188 		55,732 -0.8% 0.18 US$10,188
2024-08-07 2024-08-05 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
164,523 -2.4%
0.19
US$30,996 		164,523 -2.4% 0.19 US$30,996
2024-08-05 2024-08-02 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
286,200 -4.0%
0.20
US$57,354 		286,200 -4.0% 0.20 US$57,354
2024-08-05 2024-08-01 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
63,564 -0.9%
0.22
US$13,743 		63,564 -0.9% 0.22 US$13,743
2024-07-30 2024-07-30 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
756,835 -9.5%
0.22
US$167,185 		756,835 -9.5% 0.22 US$167,185
2024-07-30 2024-07-29 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
363,949 -4.4%
0.24
US$85,637 		363,949 -4.4% 0.24 US$85,637
2024-07-30 2024-07-26 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
258,335 -3.0%
0.24
US$62,440 		258,335 -3.0% 0.24 US$62,440
2024-06-24 2024-06-21 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
115,000 +20.3%
0.27
US$30,716 		115,000 +20.3% 0.27 US$30,716
2024-06-24 2024-06-20 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
190,000 +50.6%
0.25
US$48,108 		190,000 +50.6% 0.25 US$48,108
2024-06-20 2024-06-18 B Purchase
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
17,500 +32.9%
0.25
US$4,335 		17,500 +32.9% 0.25 US$4,335
2023-09-25 2023-09-22 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
30,403 +8.8%
1.38
US$41,956 		30,403 +8.8% 1.38 US$41,956
2023-09-25 2023-09-21 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
35,000 +11.3%
1.38
US$48,300 		35,000 +11.3% 1.38 US$48,300
2023-05-18 2023-05-17 S Sale
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
3,700 -6.5%
1.95
US$7,215 		3,700 -6.5% 1.95 US$7,215
2023-05-17 2023-05-17 PrS Proposed sale
3.4
Hahn Brian M.

Officer

Officer
4,313
1.96
US$8,453 		4,313 1.96 US$8,453
2023-05-11 2023-05-10 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
30,000 +47.4%
1.56
US$46,800 		30,000 +47.4% 1.56 US$46,800
2023-05-09 2023-05-08 B Purchase
2.4
Johnson Bruce S

SVP & Chief Commercial Officer

Officer
13,500 +10.8%
1.57
US$21,195 		13,500 +10.8% 1.57 US$21,195
2023-02-28 2023-02-24 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
100,000 +1.2%
1.70
US$170,000 		100,000 +1.2% 1.70 US$170,000
2023-02-23 2023-02-23 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
200,000 +2.4%
1.75
US$350,760 		200,000 +2.4% 1.75 US$350,760
2023-02-23 2023-02-22 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
150,000 +1.8%
1.79
US$268,995 		150,000 +1.8% 1.79 US$268,995
2023-02-23 2023-02-21 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
50,000 +0.6%
1.85
US$92,500 		50,000 +0.6% 1.85 US$92,500
2023-02-17 2023-02-17 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
200,000 +2.5%
1.71
US$341,000 		200,000 +2.5% 1.71 US$341,000
2023-02-17 2023-02-16 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
315,266 +4.2%
1.68
US$531,129 		315,266 +4.2% 1.68 US$531,129
2023-02-17 2023-02-15 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
1,000,000 +15.2%
2.16
US$2,155,800 		1,000,000 +15.2% 2.16 US$2,155,800
2023-02-13 2023-02-09 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
11,451 +0.2%
3.24
US$37,123 		11,451 +0.2% 3.24 US$37,123
2023-01-27 2023-01-26 S Sale
2.4
SANDELL SCOTT D
Large shareholder
1,351,092 -37.7%
3.12
US$4,213,786 		1,351,092 -37.7% 3.12 US$4,213,786
2023-01-27 2023-01-26 S Sale
2.4
SANDELL SCOTT D
Large shareholder
1,648,908 -37.7%
3.12
US$5,142,614 		1,648,908 -37.7% 3.12 US$5,142,614
2023-01-27 2023-01-25 S Sale
2.4
SANDELL SCOTT D
Large shareholder
293,645 -7.6%
3.26
US$958,428 		293,645 -7.6% 3.26 US$958,428
2023-01-27 2023-01-25 S Sale
2.4
SANDELL SCOTT D
Large shareholder
358,371 -7.6%
3.26
US$1,169,687 		358,371 -7.6% 3.26 US$1,169,687
2023-01-06 2023-01-05 S Sale
2.4
SANDELL SCOTT D
Large shareholder
32,139 -0.8%
2.76
US$88,659 		32,139 -0.8% 2.76 US$88,659
2023-01-06 2023-01-05 S Sale
2.4
SANDELL SCOTT D
Large shareholder
39,223 -0.8%
2.76
US$108,201 		39,223 -0.8% 2.76 US$108,201
2023-01-04 2023-01-04 S Sale
2.4
SANDELL SCOTT D
Large shareholder
45,930 -1.2%
2.91
US$133,643 		45,930 -1.2% 2.91 US$133,643
2023-01-04 2023-01-04 S Sale
2.4
SANDELL SCOTT D
Large shareholder
56,054 -1.2%
2.91
US$163,100 		56,054 -1.2% 2.91 US$163,100
2023-01-04 2023-01-03 S Sale
2.4
SANDELL SCOTT D
Large shareholder
78,730 -1.9%
2.99
US$235,411 		78,730 -1.9% 2.99 US$235,411
2023-01-04 2023-01-03 S Sale
2.4
SANDELL SCOTT D
Large shareholder
96,084 -1.9%
2.99
US$287,301 		96,084 -1.9% 2.99 US$287,301
2023-01-04 2022-12-30 S Sale
2.4
SANDELL SCOTT D
Large shareholder
54,645 -1.3%
3.02
US$165,028 		54,645 -1.3% 3.02 US$165,028
2023-01-04 2022-12-30 S Sale
2.4
SANDELL SCOTT D
Large shareholder
66,690 -1.3%
3.02
US$201,404 		66,690 -1.3% 3.02 US$201,404
2022-12-27 2022-12-22 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
110,000 +55.0%
2.25
US$247,500 		110,000 +55.0% 2.25 US$247,500
2022-11-18 2022-11-17 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
20,000 +46.2%
1.87
US$37,400 		20,000 +46.2% 1.87 US$37,400
2022-11-16 2022-11-15 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
100,000 +100.0%
1.66
US$166,000 		100,000 +100.0% 1.66 US$166,000
2022-11-16 2022-11-14 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
100,000 +inf%
1.43
US$143,000 		100,000 +inf% 1.43 US$143,000
2022-11-14 2022-11-11 B Purchase
3.3
PEARSON TIMOTHY R
Non-Executive Director
19,400 +369.5%
1.29
US$25,026 		19,400 +369.5% 1.29 US$25,026
2022-11-14 2022-11-11 B Purchase
3.3
Semerjian Harout

Chief Executive Officer

Executive Director
25,000 +inf%
1.29
US$32,250 		25,000 +inf% 1.29 US$32,250
2022-11-14 2022-11-11 B Purchase
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
20,000 +54.3%
1.06
US$21,200 		20,000 +54.3% 1.06 US$21,200
2022-11-14 2022-11-11 B Purchase
3.8
Girard Armand

SVP, Chief Business Officer

Officer
6,500 +28.7%
1.05
US$6,825 		6,500 +28.7% 1.05 US$6,825
2022-11-14 2022-11-11 B Purchase
3.8
Magnani John L.

SVP of Research, CSO

Officer
45,045 +14.0%
1.17
US$52,703 		45,045 +14.0% 1.17 US$52,703
2022-03-10 2022-03-09 S Sale
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
2,917 -7.3%
1.09
US$3,180 		2,917 -7.3% 1.09 US$3,180
2022-03-10 2022-03-09 S Sale
3.8
Magnani John L.

SVP of Research, CSO

Officer
3,227 -1.0%
1.09
US$3,517 		3,227 -1.0% 1.09 US$3,517
2022-03-10 2022-03-09 S Sale
3.8
Girard Armand

SVP, Chief Business Officer

Officer
2,339 -9.4%
1.09
US$2,550 		2,339 -9.4% 1.09 US$2,550
2021-11-18 2021-11-16 B Purchase
0.5
Andrews Patricia S
Non-Executive Director
40,000 +761.9%
2.05
US$82,000 		40,000 +761.9% 2.05 US$82,000
2020-12-30 2020-12-28 PlS Planned sale
2.3
King Rachel K.

President, CEO

Executive Director
84,176 -19.1%
3.91
US$329,128 		84,176 -19.1% 3.91 US$329,128
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
86,090 +15.8%
2.60
US$223,834 		86,090 +15.8% 2.60 US$223,834
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
506,155 +15.8%
2.60
US$1,316,003 		506,155 +15.8% 2.60 US$1,316,003
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
674,492 +15.7%
2.60
US$1,753,679 		674,492 +15.7% 2.60 US$1,753,679
2020-11-03 2020-10-30 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
15,472 +2.9%
2.75
US$42,548 		15,472 +2.9% 2.75 US$42,548
2020-11-03 2020-10-30 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
250,755 +8.5%
2.75
US$689,576 		250,755 +8.5% 2.75 US$689,576
2020-11-03 2020-10-30 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
666,385 +18.3%
2.75
US$1,832,559 		666,385 +18.3% 2.75 US$1,832,559
2020-03-10 2020-03-09 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
20,000 +111.1%
3.40
US$68,000 		20,000 +111.1% 3.40 US$68,000
2019-09-09 2019-09-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
124,956 +30.9%
3.18
US$397,610 		124,956 +30.9% 3.18 US$397,610
2019-09-09 2019-09-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
689,834 +30.4%
3.18
US$2,195,052 		689,834 +30.4% 3.18 US$2,195,052
2019-09-09 2019-09-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
853,956 +30.7%
3.18
US$2,717,288 		853,956 +30.7% 3.18 US$2,717,288
2019-08-15 2019-08-13 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
10,000 +125.0%
3.18
US$31,800 		10,000 +125.0% 3.18 US$31,800
2018-10-18 2018-10-18 S Sale
3.5
Magnani John L.

SVP of Research, CSO

Executive Director
3,527 -4.4%
14.02
US$49,449 		3,527 -4.4% 14.02 US$49,449
2018-10-18 2018-10-17 S Sale
3.5
Magnani John L.

SVP of Research, CSO

Executive Director
7,273 -8.4%
14.00
US$101,822 		7,273 -8.4% 14.00 US$101,822
2018-10-18 2018-10-16 S Sale
3.5
Magnani John L.

SVP of Research, CSO

Executive Director
14,200 -14.1%
14.01
US$198,942 		14,200 -14.1% 14.01 US$198,942
2018-06-12 2018-06-11 S Sale
3.1
Hahn Brian M.

CFO
19,345 -100.0%
18.04
US$348,984 		19,345 -100.0% 18.04 US$348,984
2018-05-11 2018-05-10 S Sale BARRIS PETER J Large shareholder
5,533 -0.1%
17.81
US$98,543 		5,533 -0.1% 17.81 US$98,543
2018-05-11 2018-05-10 S Sale BARRIS PETER J Large shareholder
4,006 -0.1%
17.81
US$71,347 		4,006 -0.1% 17.81 US$71,347
2018-05-11 2018-05-10 S Sale
2.4
SANDELL SCOTT D
Large shareholder
5,533 -0.1%
17.81
US$98,543 		5,533 -0.1% 17.81 US$98,543
2018-05-11 2018-05-10 S Sale
2.4
SANDELL SCOTT D
Large shareholder
4,006 -0.1%
17.81
US$71,347 		4,006 -0.1% 17.81 US$71,347
2018-05-11 2018-05-10 S Sale
3.1
BARRETT M JAMES
Non-Executive Director Large shareholder
5,533 -0.1%
17.81
US$98,543 		5,533 -0.1% 17.81 US$98,543
2018-05-11 2018-05-10 S Sale
3.1
BARRETT M JAMES
Non-Executive Director Large shareholder
4,006 -0.1%
17.81
US$71,347 		4,006 -0.1% 17.81 US$71,347
2018-05-11 2018-05-10 S Sale NEW ENTERPRISE ASSOCIATES 10 L P Large shareholder
5,533 -0.1%
17.81
US$98,543 		5,533 -0.1% 17.81 US$98,543
Explore more

More insider trading research around Crescent Biopharma Inc

More insider trades in KY
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity